anxiety – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:19:03 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg anxiety – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Pregabalin Market 2021-2025 https://www.cri-report.com/report-on-chinas-pregabalin-market/ Mon, 19 Jul 2021 02:43:42 +0000 https://www.cri-report.com/?post_type=product&p=13254 In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

The post Investigation Report on China’s Pregabalin Market 2021-2025 first appeared on CRI Report.

]]> China’s Pregabalin market size increased year by year from 2016 to 2020, according to CRI’s research. Among them, the growth in sales value in 2019 was the most obvious. The sales value of Pregabalin reached CNY143 million in 2019, with an annual growth rate of 57.19%. The main reason is that Pregabalin was approved for new indications in China from 2018 to 2019, and the NMPA lifted the restriction on Pregabalin medical insurance indications in 2019, which led to a substantial increase in its sales volume and sales value.

In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another.

In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China’s Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.

CRI expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to CRI’s market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.

 

Topics Covered in Investigation Report on China’s Pregabalin Market 2021-2025

  • -The impact of COVID-19 on China’s Pregabalin market
  • – Sales value of China’s Pregabalin 2016-2020
  • – Competitive landscape of China’s Pregabalin market
  • – Prices of Pregabalin in China
  • – Prices of Pregabalin in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Pregabalin market
  • – Prospect of China’s Pregabalin market from 2021 to 2025

Investigation Report on Chinese Pregabalin Market, 2020-2024

The post Investigation Report on China’s Pregabalin Market 2021-2025 first appeared on CRI Report.

]]>